Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications

OBJECTIVE: To better understand exenatide’s role in the treatment of type 2 diabetes, this analysis assessed its cost-effectiveness in comparison to an intermediate (NPH) and long-acting insulin (glargine). Exenatide is a recently approved medication for the treatment of type 2 diabetes for use in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Edwards, Krystal L., Irons, Brian K., Xu, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas 2006
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156845/
https://www.ncbi.nlm.nih.gov/pubmed/25214899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156845/
https://www.ncbi.nlm.nih.gov/pubmed/25214899

Ejemplares similares